Schrodinger jumps after Citron likens to Tesla, puts $80 target on shares

Andrew Left's Citron Research calls Schrodinger (SDGR) the most important initial public offering in the past five years and says the similarities between the company and Tesla (TSLA) are "too obvious to ignore." Both Tesla and Schrodinger were founded on the premise of using technology and software to solve problems of humanity, Citron wrote in a new report posted on its website. "In the case of Tesla, carbon emissions and Schrodinger, expediting the drug development process through software that advances chemistry beyond limits ever imagined," the firm contends. "With the massive premiums being paid for pharma companies with disruptive drug assets, Citron expects Wall Street to quickly re-rate Schrodinger shares much higher," the firm best known for short selling concludes. Citron placed an $80 price target on Schrodinger shares. The stock in midday trading is up 7%, or $2.45, to $38.17. Reference Link